

# Major R&D Pipeline: 5DXd-ADCs

Phase 1		Phase 2		Phase 3		Filed	
(US/EU/Asia) HER2+ BC 2L+/1L DESTINY-Breast07	(JP/US) solid tumors TROPION-PanTumor01	(US/EU/Asia) TNBC (durvalumab combo) BEGONIA	(JP/US/EU/Asia) solid tumors TROPION-PanTumor03	(JP/US/EU/Asia) HER2+ BC adjuvant* <sup>1</sup> DESTINY-Breast05	(JP/EU) HER2 mutant NSCLC 2L+ DESTINY-Lung01/Lung02		
(US/EU/Asia) HER2 low BC Chemo naïve/ post chemo DESTINY-Breast08	(CN) NSCLC, TNBC TROPION-PanTumor02	(CN) HER2+ GC 3L DESTINY-Gastric06	(JP/US/EU/Asia) NSCLC (w/ AGA) TROPION-Lung05	(JP/US/EU/Asia) HER2 low BC chemo naïve DESTINY-Breast06			
(JP/US/EU/Asia) HER2+ GC combo, 2L+/1L DESTINY-Gastric03	(JP/US/EU/Asia) NSCLC (w/o AGA, pembrolizumab combo) TROPION-Lung02	(CN) HER2 mutant NSCLC 2L+ DESTINY-Lung05	(US/EU/Asia) TNBC (durvalumab combo) BEGONIA	(JP/US/EU/Asia) HER2+ BC 1L DESTINY-Breast09			
(US/EU/Asia) HER2+ NSCLC (durvalumab combo) 1L DESTINY-Lung03	(JP/US/EU) NSCLC (w/o AGA, durvalumab, AZD2936 and MEDI5752 combo) TROPION-Lung04	(US/EU/Asia) NSCLC (durvalumab combo) 2L+ HUDSON	(JP/US/EU/Asia) EGFR mutated NSCLC (osimertinib combo) 2L ORCHARD	(JP/US/EU/Asia) HER2+ BC neoadjuvant DESTINY-Breast11			
(US/EU) BC, bladder (nivolumab combo)	(JP/US/EU/Asia) solid tumors (AZD5305 combo) PETRA	(JP/US/EU) HER2+ CRC 3L DESTINY-CRC01	(US/EU/Asia) resectable early-stage NSCLC (durvalumab combo) neoadjuvant NeoCOAST-2	(US/EU/Asia) HER2 low BC, HER2 IHC 0 BC, 2/3L DESTINY-Breast15			
(US/EU) BC, NSCLC (pembrolizumab combo)	(JP/US/EU/Asia) NSCLC	(JP/US/EU/Asia) HER2+ CRC 3L DESTINY-CRC02	(JP/US/EU/Asia) EGFR mutated NSCLC 3L HERTHENA-Lung01	(JP/EU/Asia) HER2+ GC 2L DESTINY-Gastric04			
(US/EU/Asia) solid tumors (AZD5305 combo) PETRA	(JP/US) EGFR mutated NSCLC (osimertinib combo)	(JP/US/EU/Asia) HER2 mutant tumor DESTINY-PanTumor01	DS-7300 (JP/US/EU/Asia) ES-SCLC	(JP/US/EU/Asia) NSCLC (w/ HER2 exon 19 or exon 20 mutation) 1L DESTINY-Lung04			
DS-7300 (JP/US) ESCC, CRPC, squamous NSCLC, SCLC, etc.	(JP/US) HER3+ BC	(US/EU/Asia) HER2 expressing tumor DESTINY-PanTumor02		(JP/US/EU/Asia) NSCLC 2/3L TROPION-Lung01			
DS-6000 (JP/US) Renal cell carcinoma, ovarian cancer				(JP/US/EU/Asia) non-squamous NSCLC (w/o AGA, pembrolizumab combo) 1L TROPION-Lung07			
				(JP/US/EU/Asia) NSCLC (w/o AGA, pembrolizumab combo) 1L TROPION-Lung08			
				(JP/US/EU/Asia) BC <sup>*2</sup> 2/3L TROPION-Breast01			
				(JP/US/EU/Asia) TNBC 1L TROPION-Breast02			
				(JP/US/EU/Asia) TNBC (mono or durvalumab combo) adjuvant <sup>*3</sup> TROPION-Breast03			
				(JP/US/EU/Asia) EGFR mutated NSCLC 2L HERTHENA-Lung02			

■ T-DXd   
 ■ Dato-DXd   
 ■ HER3-DXd   
 ■ DS-7300   
 ■ DS-6000

□ Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials

★ Breakthrough Designation (US)   
 ★ Orphan drug designation (designated in at least one country/region among JP, US and EU)

- \* 1 Adjuvant therapy for HER2 positive breast cancer patients with residual invasive disease following neoadjuvant therapy
- \* 2 HR+, HER2 low or negative BC
- \* 3 Adjuvant therapy for TNBC patients with residual invasive disease following neoadjuvant therapy

AGA: actionable genomic alterations, BC: breast cancer, CRC: colorectal cancer, CRPC: castration-resistant prostate cancer, ESCC: esophageal squamous cell carcinoma, ES-SCLC: extensive stage-small cell lung cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, SCLC: small cell lung cancer, TNBC: triple negative breast cancer

# Major R&D Pipeline: Next Wave

Phase 1		Phase 2		Phase 3		Filed	
DS-1055 (JP/US) Anti-GARP antibody Solid tumors	DS-7011 (US) Anti-TLR7 antibody Systemic lupus erythematosus	Valemetostat (DS-3201)(JP/US/EU/Asia) EZH1/2 inhibitor PTCL		Pexidartinib (JP/Asia) CSF-1/KIT/FLT3 inhibitor Tenosynovial giant cell tumor	Quizartinib (EU) FLT3 inhibitor AML 1L		
DS-1594 (US) Menin-MLL binding inhibitor AML, ALL	DS-2325 (US) KLK5 inhibitor Netherton syndrome	Valemetostat (DS-3201) (EU) EZH1/2 inhibitor BCL		Esaxerenone (JP) MR blocker Diabetic nephropathy	Mirogabalin (CN) α2δ ligands Diabetic peripheral neuropathic pain		
DS-9606 (US/EU) Target undisclosed ADC Solid tumors		DS-1001 (JP) Mutant IDH1 inhibitor Glioma		VN-0102/JVC-001 (JP) Measles mumps rubella combined vaccine	DS-5670 (JP) COVID-19 mRNA vaccine (original strain) COVID-19 mRNA vaccine (original strain) COVID-19 (booster vaccination)		
DS-1103 Anti-SIRPα antibody HER2 expressing or mutant advanced metastatic solid tumors, HER2 low BC (ENHERTU® combo)		DS-1211 (US/EU) TNAP inhibitor Pseudoxanthoma elasticum		DS-5670 (JP) COVID-19 mRNA vaccine (mutant strain), COVID-19 COVID-19 mRNA vaccine (mutant strain) COVID-19 (booster vaccination, 12 to 17 aged children)			
DS-3939 Anti-TA-MUC1 ADC Solid tumors (in prep.)		DS-5670 (JP) COVID-19 mRNA vaccine (mutant strain), COVID-19 COVID-19 mRNA vaccine (mutant strain) COVID-19 (booster vaccination, 5 to 11 aged children) (in prep.)		DS-5670 (JP) COVID-19 mRNA vaccine (mutant strain) COVID-19 (booster vaccination, 12 years old and over)			
DS-1471 Anti-CD147 antibody Solid tumors (in prep.)		VN-0200 (JP) RS virus vaccine RS virus infection		DS-5670 (JP) COVID-19 mRNA vaccine (mutant strain), COVID-19 COVID-19 mRNA vaccine (mutant strain) COVID-19 (booster vaccination, 5 to 11 aged children)			

- Oncology
- Specialty medicine
- Vaccine
- Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials
- SAKIGAKE Designation (JP) Orphan drug designation (designated in at least one country/region among JP, US and EU) Rare Pediatric Disease Designation (US)
- Fast Track Designation (US) Breakthrough Designation (US)

ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, BCL: B cell lymphoma, LBCL: large B cell lymphoma, PTCL: peripheral T-cell lymphoma